THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA

摘要

Disclosed herein are therapeutic treatment protocols designed for thetreatment of B cell lymphoma. These protocols arebased upon therapeutic strategies which include the use of administration ofimmunologically active mouse/human chimeric anti-CD20antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategiescomprising the use of chimeric anti-CD20 antibodiesand radiolabeled anti-CD20 antibodies.